 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

Current Price	$0.4758
Prev Close	$0.4758
Open	$0.5253
Dividend Yield	0.00%
50-Day Moving Average	$0.5277
Beta	0.61
Avg. Volume	41,783.71
PE Ratio	-0.20

52-Week High	$7.13
52-Week Low	$0.3568
Market Capitalization	$7.46M
EPS	-$2.53
Price to Book	0.88
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.13

AYLA Ayala Pharmaceuticals Inc

About

Feed

Fundamentals

News